Abu Dhabi, UAE: The Abu Dhabi Stem Cells Centre (ADSCC) has announced a significant breakthrough in Huntington’s disease research, identifying a previously unrecognised disease mechanism that could open new avenues for the development of targeted treatments for the inherited neurological disorder.
The findings, generated using patient-derived stem cell technology and advanced brain models, are expected to be published in a peer-reviewed scientific journal. Researchers say the discovery could contribute to the development of future therapies aimed at addressing the underlying biological mechanisms driving Huntington’s disease.
Huntington’s disease is a rare, progressive genetic disorder that causes the gradual deterioration of movement, cognitive abilities and behavioural control. Despite decades of research, treatment options remain limited, and there is currently no therapy that directly addresses the root cause of the disease.
As part of the study, the ADSCC research team developed advanced laboratory models using skin and blood cells collected from patients with Huntington’s disease at different stages of the condition, including both paediatric and adult patients.
The cells were reprogrammed into induced pluripotent stem cells (iPSCs) and subsequently differentiated into brain tissue containing neurons and astrocytes. This approach enabled researchers to investigate disease mechanisms in a patient-specific laboratory environment.
The research identified a potentially important role for astrocytes in the progression of Huntington’s disease. Astrocytes are specialised support cells that perform essential functions in the brain and contribute to maintaining the health and normal functioning of neurons.
According to the research findings, astrocytes affected by Huntington’s disease are unable to properly build and maintain their internal structural framework as a result of the mutant huntingtin protein.
The study found that the abnormal protein disrupts three critical molecular pathways involved in regulating the production of Glial Fibrillary Acidic Protein (GFAP), a key structural component required for maintaining healthy astrocyte structure and function.
To validate their findings, researchers introduced the mutant huntingtin protein into healthy cells and were able to reproduce cellular abnormalities similar to those observed in patient-derived models. The team subsequently evaluated three therapeutic compounds designed to restore the disrupted molecular pathways.
Following treatment, the affected astrocytes demonstrated recovery of their normal structure and function, suggesting that targeting these molecular pathways may offer a potential direction for future therapeutic research.
The findings also highlight the potential of patient-derived stem cell platforms in advancing research into inherited neurological and genetic diseases. The technology could potentially support investigations into a range of conditions, including amyotrophic lateral sclerosis (ALS), leukodystrophies, Alzheimer’s disease, Parkinson’s disease, Alexander disease, sickle cell disease and other rare disorders that may have particular relevance to populations in the region.
The research represents another step toward understanding the complex biological mechanisms underlying Huntington’s disease and demonstrates the potential of advanced stem cell models to accelerate the discovery and testing of future precision therapies.
